Strategic report Corporate governance Financial statements Financial statements Notes to the consolidated financial statements continued 38.
Related parties Transactions between the Company and its subsidiaries have been eliminated on consolidation and are not disclosed in this note.
Executive incentive plan Transactions between the Group and its associates and other related parties are disclosed below.
The 2014 Executive Incentive Plan EIP was approved by shareholders at the 2014 Annual General Meeting.
The EIP is a combined cash Trading transactions: bonus element A, deferred shares element B and restricted share element C scheme.
Under the EIP, the Company makes grants of conditional awards and $nil cost options under elements B and C to the executive directors and senior executives of the Group.
Awards During the year, Group companies entered into the following transactions with related parties: under all elements are dependent on the achievement of individual and Group KPIs over one year prior to grant.
The shares awarded under Boehringer Ingelheim GmbH BI : is a related party of Hikma because BI owns 16.7% 2015: 0.0% of the share capital of Hikma, element B are not released for a period of two years during which they are subject to a forfeiture condition.
The shares awarded under controls 11.7% 2015: 0.0% of the voting capital of Hikma, has the right to appoint a director of Hikma and a senior executive of element C are not released for a period of three years, but are not subject to a forfeiture condition.
Members of the Executives committee BI holds a directorship of Hikma.
During the year, the Group total sales to BI amounted to $90.1 million 2015: $nil and the Group total must retain 50% of the shares received from elements B and C for a period of five years from the date of grant.
purchases from BI amounted to $10.3 million.
As at the year end, the amount owed from BI to the Group was $45.2 million 2015: $nil.
2016 grants 2016 grants 2015 grants 2015 grants Total Additionally, balances arising from the acquisition of West-Ward Columbus from BI relating to contingent consideration are disclosed in Year 2016 11-May 17-Mar 15-May 10-Apr Number note 30 and purchase price adjustments which are outstanding are disclosed in note 43.
Capital Bank, Jordan Capital Bank : is a related party of Hikma because one director of Hikma is a director, the founder and former Beginning Balance 118,000 338,808 456,808 Chief Executive Officer of Capital Bank.
At the year end, total cash balance at Capital Bank was $11.3 million 2015: $9.4 million and Granted during the year 165,553 448,875 614,428 utilisation of facilities granted by Capital Bank to the Group amounted to $8.3 million 2015: $nil.
The interest expense income is within Outstanding at 31 December 165,553 448,875 118,000 338,808 1,071,236 market rate Darhold Limited Darhold : is a related party of Hikma because three directors of Hikma jointly constitute the majority of directors and 2015 grants 2015 grants Total shareholders with immediate family members in Darhold and because Darhold owns 25.00% 2015: 29.06% of the share and voting Year 2015 15-May 10-Apr Number capital of Hikma.
Beginning Balance 118,000 338,808 456,808 Granted during the year Other than dividends as paid to all shareholders, there were no transactions between the Group and Darhold Limited during the year.
Outstanding at 31 December 118,000 338,808 456,808 HikmaCure Limited HikmaCure : is a related party of Hikma because HikmaCure is a 50:50 joint venture JV with MIDROC Pharmaceuticals Limited MIDROC.
Hikma and MIDROC invested in HikmaCure in equal proportions and have committed to provide up The cost of the EIP of $13 million 2015: $4 million has been recorded in the consolidated income statement as part of general and to $22 million each in cash, of which $2.5 million has been paid 2015: $2.5 million.
Hubei Haosun Pharmaceutical Co. Ltd Haosun : is a related party of Hikma because the Group holds a non-controlling interest of The fair value per share is the face value of shares on the date of grant.
During 2016, total purchases from Haosun were $0.4 million 2015: $0.6 million.
At 31 December 2016, the amount owed from Hubei Haosun Pharmaceutical to the Group amounted to $1.7 million 2015: $nil.
Labatec Pharma Labatec : is a related party of the Group because Labatec is owned by the family of two directors of Hikma.
During The estimated 2016, total Group sales to Labatec amounted to $1.4 million 2015: $0.9 million.
As at the year end, the amount owed by Labatec to the fair value of each share Group was $0.3 million 2015: $0.2 million.
Number option The share price Date of grants granted granted at grant date Remuneration of key management personnel $ $ The remuneration of the key management personnel comprising the Executive and Non-Executive Directors and certain of senior EIPs 1 10 4 2015 338,808 33.24216 33.24216 management as set out in the Directors Report of the Group is set out below in aggregate for each of the categories specified in IAS 24 EIPs 2 15 5 2015 118,000 33.11449 33.11449 Related Party Disclosures.
Further information about the remuneration of the individual Directors is provided in the audited part of the EIPs 3 B 17 3 2016 242,608 26.97918 26.97918 Remuneration Committee Report on pages 104 to 135.
Operating lease arrangements Post-employment benefits 0.1 2016 2015 Other benefits 0.3 0.1 $m $m 26.0 20.5 Minimum lease payments under operating leases recognised in profit or loss for the year 7 8 At the balance sheet date, the Group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows: 2016 2015 $m $m Within one year 7 4 In the two to five years inclusive 18 9 After five years 12 4 37 17 Operating lease payments represent rentals payable by the Group for certain of its office properties.
Leases are negotiated for a term of one to eight years.
Annual Report 2016 193 184 Hikma Pharmaceuticals plc Annual Report 2016 185
